Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sotera Health (SHC) Cash & Equivalents (2020 - 2025)

Sotera Health (SHC) has 6 years of Cash & Equivalents data on record, last reported at $344.6 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 24.3% year-over-year to $344.6 million; the TTM value through Dec 2025 reached $344.6 million, up 24.3%, while the annual FY2025 figure was $344.6 million, 24.3% up from the prior year.
  • Cash & Equivalents reached $344.6 million in Q4 2025 per SHC's latest filing, up from $299.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $647.9 million in Q1 2023 and bottomed at $106.9 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $256.5 million, with a median of $261.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 433.55% in 2023, then tumbled 59.7% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $106.9 million in 2021, then surged by 269.65% to $395.2 million in 2022, then fell by 25.0% to $296.4 million in 2023, then dropped by 6.47% to $277.2 million in 2024, then rose by 24.3% to $344.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $344.6 million in Q4 2025, $299.2 million in Q3 2025, and $332.4 million in Q2 2025.